|
O.V. Teodorovich, M.N. Shatokhin, I.M. Kholimenko, M.I. Abdullaev, G.G. Borisenko, S.A. Naryshkin
Application of laser technologies in the treatment of non-muscle-invasive bladder cancer
|
№1 / 2022
|
|
A.Y. Zubkov, I.R. Nuriev, M.E. Sitdykova
Improvement of oncologic results of transurethral resection in the treatment
of non-muscle-invasive bladder cancer
|
№3 / 2021
|
|
A.V. Kuz’menko, V.V. Kuz’menko, T.A. Gyaurgiev
The efficacy of fesoterodine in patients after transurethral resection of the prostate
|
№1 / 2019
|
|
G.Yu. Yarin, I.A. Vil’gel’mi
An interdisciplinary approach to the management of bladder endometriosis
|
№4 / 2018
|
|
Yu.G. Alyaev, A.M. Pshikhachev, A.N. Perekalina
The risk of bladder cancer in patients with prostatic hyperplasia and strategies to manage this combination
|
№5 / 2016
|
|
P.V. Glybochko, Yu.G. Alyaev, A.M. Pshikhachev, N.I. Sorokin, A.M. Dymov
Choosing treatment for patients with bladder cancer combined with prostatic hyperplasia
|
№5 / 2016
|
|
A.I. Rolevich, A.A. Evmenenko
A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect
|
№4 / 2016
|
|
A.Ju. Zubkov, Je.N. Sitdykov, I.R. Nuriev, M.Je. Sitdykova
Intraoperative control of the effectiveness of transurethral resection of non-muscle-invasive bladder cancer
|
№2 / 2015
|
|
A.G. Martov, D.V. Ergakov, A.S. Andronov, N.A. Baykov
Transurethral electroenucleation of benign prostatic hyperplasia
|
№5 / 2014
|
|
E.V. Kulchavenya, E.V. Brizhatyuk
Bladder leukoplakia – is the surgical aggression justified?
|
№4 / 2014
|
|
R.M. Kadiev, T.I. Derevyanko
Experience of the use of drug urorec: efficacy and safety
|
№3 / 2014
|
|
Sergienko N.F., Vasilchenko M.I., Kudryashov O.I., Bega- yev A.I., Schekochihin A.V., Shsrshnev S.P., Reynuk O.L., Lototsky M.M.
On the question of the so-called
|
№4 / 2012
|
Русский
